Eli Lilly and Company

Eli Lilly shares trade at a P/E of 43.17, a premium that the numbers justify. Revenue grew 49.6% year over year, EPS surged 94.6%, and net margin hit 33.5%. The stock sits well off its 52-week high of $1,292.65, currently near $712. The Alpha Score of 60.3 reflects quality at 87 and value at 60.5, with momentum and sentiment neutral. The question for the coming quarters is whether the growth trajectory can sustain the multiple. Watch next week's earnings call for guidance on tirzepatide demand and pipeline updates.

Eli Lilly closed near the top of its 52-week range, which spans $694.23 to $1292.65. The stock trades at a P/E of 43.17, reflecting the market's willingness to pay for its 49.6% revenue growth and 94.6% EPS expansion over the past year. Net margin stands at 33.5%, among the highest in healthcare. The Alpha Score of 68 is supported by quality (87) and momentum (70.3), while value (60.5) and sentiment (50) are more neutral. The quality score reflects strong profitability and balance sheet metrics. With the stock near the upper end of its range, the next catalyst will be the quarterly earnings report, expected in late April. Investors will watch whether growth rates can sustain at these levels and if pipeline updates provide further support.

Eli Lilly shares sit near the upper end of a $694-$1,292 range, supported by 50% revenue growth and a 95% jump in EPS over the past year. The company's net margin of 33.5% reflects the pricing power of its diabetes and weight-loss drug portfolio, which continues to drive expansion. At 43 times earnings, the multiple is elevated but backed by a quality Alpha sub-score of 87 and a momentum reading of 66. Sentiment, at 50, sits neutral — the stock is priced for execution rather than surprise. Forward watch: investors will look for Wednesday's weekly prescription data to confirm demand trends for tirzepatide and any early signals on the next-generation oral candidate.

Eli Lilly shares are trading near the upper half of their 52-week range, supported by a 94.6% jump in EPS and 49.6% revenue growth. The stock carries a P/E of 43.17, elevated but backed by a net margin of 33.5% and an Alpha Score of 69.4. Momentum remains the standout pillar at 75.1, while quality scores 87, reflecting strong profitability. Sentiment lags at 50, suggesting not all analysts have fully priced in the growth trajectory. With EPS growth outpacing revenue, margin expansion is driving the story. The next catalyst to watch: second-quarter earnings and any pipeline updates on obesity-drug trial data.

Eli Lilly continues to deliver on its growth story. Revenue surged 49.6% year over year, while EPS jumped 94.6%. Net margins sit at 33.5%, reflecting strong pricing power and operational efficiency. The stock trades at 43 times earnings, a premium that the market has been willing to pay given the trajectory. The Alpha Score of 71.8 is driven by quality (87) and momentum (83.1), with value lagging at 60.5 — hardly a surprise at this multiple. The 52-week range of $694 to $1,292 shows the stock has nearly doubled, but the question is whether the pace can hold. Watch for the next FDA approval cycle and any updates on the obesity drug pipeline. That's where the next leg of the story will come from.